cimetidine has been researched along with pantoprazole in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Avdeef, A; Tam, KY | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gönne, S; Kromer, W; Postius, S; Riedel, R | 1 |
| Berstad, A; Hatlebakk, JG | 1 |
| Anic, T; Aralica, G; Bilic, I; Buljat, G; Ivankovic, D; Mikus, D; Mise, S; Perovic, D; Petek, M; Prkacin, I; Rotkvic, I; Rucman, R; Seiwerth, S; Separovic, J; Sikiric, P; Stancic-Rokotov, D; Zoricic, I | 1 |
| Huggins, RM; Latour, JK; Scates, AC | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Fantus, R; Field, BG; Graepel, J; Karlstadt, R; Lynn, R; Morris, J; Somberg, L | 1 |
| Lin, HJ; Tsai, JJ | 1 |
| Chang, CH; Hsu, PI; Huang, YB; Lin, PC; Tseng, PL | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Fruth, A; Pees, M; Rabsch, W; Renfert, K; Speck, S | 1 |
5 review(s) available for cimetidine and pantoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cimetidine; Drug Administration Schedule; Enzyme Inhibitors; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Injections, Intravenous; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine; Sulfoxides | 2003 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cimetidine; Critical Care; Histamine H2 Antagonists; Humans; Odds Ratio; Omeprazole; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Ranitidine; Risk; Stress, Psychological | 2010 |
1 trial(s) available for cimetidine and pantoprazole
| Article | Year |
|---|---|
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedule; Female; Gastric Acid; Gastritis; Gastrointestinal Hemorrhage; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Pantoprazole; Pilot Projects; Stress, Physiological | 2008 |
14 other study(ies) available for cimetidine and pantoprazole
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Direct comparison between the ulcer-healing effects of two H(+)-K(+)-ATPase inhibitors, one M1-selective antimuscarinic and one H2 receptor antagonist in the rat.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Duodenal Ulcer; H(+)-K(+)-Exchanging ATPase; Histamine H2 Antagonists; Male; Muscarinic Antagonists; Omeprazole; Pantoprazole; Parasympatholytics; Pirenzepine; Rats; Rats, Inbred Strains; Stomach Ulcer; Sulfoxides | 1990 |
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Atropine; Benzimidazoles; Bromocriptine; Cimetidine; Disease Models, Animal; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Indomethacin; Lansoprazole; Male; Mice; Mice, Inbred Strains; Misoprostol; Omeprazole; Pantoprazole; Peptide Fragments; Proteins; Ranitidine; Stomach Diseases; Sulfoxides | 2001 |
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stressed related mucosal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cimetidine; Critical Illness; Gastric Mucosa; Gastrointestinal Hemorrhage; Humans; Hydrogen-Ion Concentration; Pantoprazole; Stomach Diseases; Stress, Physiological | 2008 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
The use of a salmonella bacteriophage in bearded dragons: application, passage time and reisolation.
Topics: Animals; Buffers; Child; Cimetidine; Cloaca; Feces; Female; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Immunocompromised Host; Lizards; Male; Pantoprazole; Pets; Proton Pump Inhibitors; Salmonella Infections; Salmonella Infections, Animal; Salmonella Phages; Stomach; Time Factors; Zoonoses | 2019 |